Soluble vascular endothelial growth factor receptor-1 (sFLT-1) mediates downregulation of FLT-1 and prevents activated neutrophils from women with preeclampsia from additional migration by VEGF

Circulation Research

Volumn 97, Issue 12, 2005, Pages 1253-1261

  Krysiak, Oliver ^a   Bretschneider, Anja ^a   Zhong, Enhong ^a   Webb, Jessie ^a   Hopp, Hartmut ^a   Verlohren, Stefan ^a   Fuhr, Norbert ^a   Lanowska, Malgorzata ^b   Nonnenmacher, Andreas ^b   Vetter, Roland ^a   Jankowski, Joachim ^a   Paul, Martin ^a   Schönfelder, Gilbert ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Charité Universitätsmedizin Berlin ^*

Author keywords

Migration; Neutrophils; Preeclampsia; Pregnancy; VEGF receptor 1

Indexed keywords

SOLUBLE VASCULOTROPIN RECEPTOR 1; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; FLT1 PROTEIN, HUMAN; VASCULOTROPIN A;

ADULT; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; LEUKOCYTE ACTIVATION; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PATHOPHYSIOLOGY; PREECLAMPSIA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; BLOOD; CELL CULTURE; CELL MOTION; CHEMISTRY; DOWN REGULATION; GENETICS; NEUTROPHIL; PHYSIOLOGY; PREGNANCY;

CELL MOVEMENT; CELLS, CULTURED; DOWN-REGULATION; FEMALE; HUMANS; NEUTROPHIL ACTIVATION; NEUTROPHILS; PRE-ECLAMPSIA; PREGNANCY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 31944436278     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000194324.29363.82     Document Type: Article

References (37)

1. Dekker GA, Sibai BM. Etiology and pathogenesis of preeclampsia: current concepts. Am J Obstet Gynecol. 1998;179:1359-1375.
2. Conrad KP, Miles TM, Benyo DF. Circulating levels of immunoreactive cytokines in women with preeclampsia. Am J Reprod Immunol. 1998;40:102-111.
3. Greer IA, Haddad NG, Dawes J, Johnstone FD, Calder AA. Neutrophil activation in pregnancy-induced hypertension. Br J Obstet Gynaecol. 1989;96:978-982.
4. Clark P, Boswell F, Greer IA. The neutrophil and preeclampsia. Semin Reprod Endocrinol. 1998;16:57-64.
5. Greer IA, Dawes J, Johnston TA, Calder AA. Neutrophil activation is confined to the maternal circulation in pregnancy-induced hypertension. Obstet Gynecol. 1991;78:28-32.
6. Mellembakken JR, Hogasen K, Mollnes TE, Hack CE, Abyholm T, Videm V. Increased systemic activation of neutrophils but not complement in preeclampsia. Obstet Gynecol. 2001;97:371-374.
7. Wang Y, Gu Y, Zhang Y, Lewis DF. Evidence of endothelial dysfunction in preeclampsia: decreased endothelial nitric oxide synthase expression is associated with increased cell permeability in endothelial cells from preeclampsia. Am J Obstet Gynecol. 2004;190:817-824.
8. Lee VM, Quinn PA, Jennings SC, Ng LL. Neutrophil activation and production of reactive oxygen species in pre-eclampsia. J Hypertens. 2003;21:395-402.
9. Wang Y, Adair CD, Coe L, Weeks JW, Lewis DF, Alexander JS. Activation of endothelial cells in preeclampsia: increased neutrophil-endothelial adhesion correlates with up-regulation of adhesion molecule P-selectin in human umbilical vein endothelial cells isolated from pre-eclampsia. J Soc Gynecol Investig. 1998;5:237-243.
10. Sibai B, Dekker G, Kupferminc M Pre-eclampsia. Lancet. 2005;365:785-799.
11. Wang Y, Gu Y, Philibert L, Lucas MJ. Neutrophil activation induced by placental factors in normal and pre-eclamptic pregnancies in vitro. Placenta. 2001;22:560-565.
12. Brenchley PE, Ralph SA, Summers A. VEGF polymorphisms and renal pathologies. Advances in nephrology from the Necker Hospital. 2002;32:17-23.
13. Luttun A, Autiero M, Tjwa M, Carmeliet P Genetic dissection of tumor angiogenesis : are PlGF and VEGFR-1 novel anti-cancer targets? Biochim Biophys Acta. 2004;1654:79-94.
14. Ancelin M, Chollet-Martin S, Herve MA, Legrand C, El Benna J, Perrot-Applanat M. Vascular endothelial growth factor VEGF189 induces human neutrophil chemotaxis in extravascular tissue via an autocrine amplification mechanism. Lab Invest. 2004;84:502-512.
15. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 1996;87:3336-3343.
16. Clauss M, Weich H, Breier G, Knies U, Rockl W, Waltenberger J, Risau W. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem. 1996;271:17629-17634.
17. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA. 1998;95:9349-9354.
18. Banks RE, Forbes MA, Searles J, Pappin D, Canas B, Rahman D, Kaufmann S, Walters CE, Jackson A, Eves P, Linton G, Keen J, Walker JJ, Selby PJ. Evidence for the existence of a novel pregnancy-associated soluble variant of the vascular endothelial growth factor receptor, Flt-1. Mol Hum Reprod. 1998;4:377-386.
19. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, Scholz D, Acker T, DiPalma T, Dewerchin M, Noel A, Stalmans I, Barra A, Blacher S, Vandendriessche T, Ponten A, Eriksson U, Plate KH, Foidart JM, Schaper W, Chamock-Jones DS, Hicklin DJ, Herbert JM, Collen D, Persico MG. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 2001;7:575-583.
20. Clauss M. Functions of the VEGF Receptor-1 (FLT-1) in the Vasculature. Trends Cardiovasc Med. 1998;8:241-245.
21. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649-658.
22. McKeeman GC, Ardill JE, Caldwell CM, Hunter AJ, McClure N. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol. 2004;191:1240-1246.
23. Schonfelder G, John M, Hopp H, Fuhr N, van-Der-Giet M, Paul M. Expression of inducible nitric oxide synthase in placenta of women with gestational diabetes. Faseb J. 1996;10:777-784.
24. Barleon B, Siemeister G, Martiny-Baron G, Weindel K, Herzog C, Marme D Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells. Cancer Res. 1997;57:5421-5425.
25. Funke-Kaiser H, Reichenberger F, Kopke K, Herrmann SM, Pfeifer J, Orzechowski HD, Zidek W, Paul M, Brand E Differential binding of transcription factor E2F-2 to the endothelin-converting enzyme-1b promoter affects blood pressure regulation. Hum Mol Genet. 2003;12:423-433.
26. Valter MM, Hugel A, Huang HJ, Cavenee WK, Wiestler OD, Pietsch T, Wernert N Expression of the Ets-1 transcription factor in human astrocytomas is associated with Fms-like tyrosine kinase-1 (Flt-1)/vascular endothelial growth factor receptor-1 synthesis and neoangiogenesis. Cancer Res. 1999;59:5608-5614.
27. Wakiya K, Begue A, Stehelin D, Shibuya M A cAMP response element and an Ets motif are involved in the transcriptional regulation of flt-1 tyrosine kinase (vascular endothelial growth factor receptor 1) gene. J Biol Chem. 1996;271:30823-30828.
28. Levine RJ, Karumanchi SA. Circulating angiogenic factors in pre-eclampsia. Clin Obstet Gynecol. 2005;48:372-386.
29. Luttun A, Carmeliet P. Soluble VEGF receptor Flt1: the elusive pre-eclampsia factor discovered? J Clin Invest. 2003;111:600-602.
30. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA Circulating angiogenic factors and the risk of pre-eclampsia. N Engl J Med. 2004;350:672-683.
31. Jelkmann W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem. 2001;47:617-623.
32. Chung JY, Song Y, Wang Y, Magness RR, Zheng J. Differential expression of vascular endothelial growth factor (VEGF), endocrine gland derived-VEGF, and VEGF receptors in human placentas from normal and preeclamptic pregnancies. J Clin Endocrinol Metab. 2004;89:2484-2490.
33. Helske S, Vuorela P, Carpen O, Hornig C, Weich H, Halmesmaki E. Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies. Mol Hum Reprod. 2001;7:205-210.
34. Ahmad S, Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res. 2004;95:884-891.
35. Luppi P How immune mechanisms are affected by pregnancy. Vaccine. 2003;21:3352-3357.
36. Redman CW, Sargent IL Latest advances in understanding preeclampsia. Science. 2005;308:1592-1594.
37. Leik CE, Walsh SW. Neutrophils infiltrate resistance-sized vessels of subcutaneous fat in women with preeclampsia. Hypertension. 2004;44:72-77.